Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
An update from Eurofins Scientific ( (FR:ERF) ) is now available.
Eurofins reported a strong first half of 2026, with basic EPS up 29% to €1.55 and revenues rising 2.5% to €3.7 billion despite currency headwinds, as benefits from its long-term investment in laboratory networks and digitalisation flowed through. Adjusted EBITDA grew 8% with margins nearing the group’s 2027 target, free cash flow jumped by roughly one-third, and leverage remained stable while the company returned €206 million via share repurchases.
Operationally, Eurofins saw improving organic growth, particularly in Life and Consumer & Technology Products Testing, a rebound in Environment Testing and expects BioPharma to accelerate in the second half. Strategically, it expanded and automated key laboratory sites, completed 17 acquisitions, launched new start-up labs and blood collection points, agreed to acquire Element Materials Technology’s North American life sciences testing business, and advanced portfolio reshaping through divestments, reinforcing its focus on specialised testing for life and its positioning against more diversified TIC competitors.
The most recent analyst rating on (FR:ERF) stock is a Sell
with a EUR60.00 price target.
To see the full list of analyst forecasts on Eurofins Scientific stock,
see the FR:ERF Stock Forecast page.
More about Eurofins Scientific
Eurofins Scientific, listed in Paris, operates a global network of testing laboratories focused on life sciences, environmental, food, clinical diagnostics and consumer product quality. The group follows a hub-and-spoke model, combining owned and leased sites, and pursues growth through digitalisation, start-up labs and targeted acquisitions in Europe, North America and other regions.
Its market focus is on highly specialised Testing, Inspection and Certification services, where it aims to differentiate from diversified TIC players through depth of expertise in core life-related testing activities. The company actively manages its portfolio, divesting non-core or underperforming units while reinvesting in strategic capacity, innovation and shareholder returns through buybacks.
Average Trading Volume: 307,498
Technical Sentiment Signal: Strong Buy
Current Market Cap: €12.26B
See more data about ERF stock on TipRanks’ Stock Analysis page.